Syndicate content World Pharma News
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements
Updated: 2 years 24 weeks ago

Selumetinib granted orphan designation in Europe for neurofibromatosis type 1

Thu, 08/09/2018 - 10:00
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) announced that the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).
Categories: Category 2

Compounds in 'monster' radish could help tame cardiovascular disease

Wed, 08/08/2018 - 12:00
Step aside carrots, onions and broccoli. The newest heart-healthy vegetable could be a gigantic, record-setting radish. In a study appearing in ACS' Journal of Agricultural and Food Chemistry, scientists report that compounds found in the Sakurajima Daikon, or "monster," radish could help protect coronary blood vessels and potentially prevent heart disease and stroke.
Categories: Category 2

FDA approves treatment for two rare types of non-Hodgkin lymphoma

Wed, 08/08/2018 - 10:00
The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This approval provides a new treatment option for patients with MF and is the first FDA approval of a drug specifically for SS.
Categories: Category 2

Taking a pill can effectively treat brutal lung disease

Tue, 08/07/2018 - 12:00
Researchers report in Nature Communications they figured out why air sacs in the lungs clog up with a thick substance called surfactant in a brutal disease called Pulmonary Alveolar Proteinosis (PAP), and they show taking cholesterol-busting pills called statins can effectively treat the disease. That's good news for people with PAP because at present the current standard treatment is something called a whole lung lavage.
Categories: Category 2

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica announce new partnership to develop first-in-class gene therapy for cystic fibrosis

Tue, 08/07/2018 - 10:00
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium (GTC) - consisting of Imperial College London and the Universities of Oxford and Edinburgh - Imperial Innovations, and Oxford BioMedica (OXB) announce a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis (CF).
Categories: Category 2

Differences in immune responses due to age, sex, and genetics

Mon, 08/06/2018 - 12:00
Over the course of our life, we are continuously exposed to pathogens such as viruses and bacteria, meaning that our immune system is constantly at work. When stimulated by either pathogen or vaccine, the immune system notably mounts what is known as a "humoral response", which corresponds to the production of antibodies that can help fight infections and provide long-term protection.
Categories: Category 2

Bayer Cares Foundation promotes sustainable growth by supporting social impact pioneers with grants totaling EUR 1 million

Mon, 08/06/2018 - 10:00
Grants4Impact (G4I), a new energizer program launched by Bayer Cares Foundation, is providing targeted support to social impact pioneers and start-ups in the fields of healthcare and nutrition. The aim of the program is to give selected change-makers around the world new opportunities to grow and transform great ideas into powerful impact solutions that help to improve the lives of millions.
Categories: Category 2

Mushrooms of the Far East hold promise for the anti-cancer therapy

Fri, 08/03/2018 - 10:00
Mushrooms from the Far East area contain the natural chemical compounds, which could be used for the design of the novel drugs with highly specific anti-tumor activities and low-toxicity. These compounds may offer new avenues for oncology, providing us with either stand-alone alternatives to chemotherapy, chemopreventive medicines, or drugs to be used in combination with other therapies.
Categories: Category 2

Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island

Thu, 08/02/2018 - 10:00
Amgen (NASDAQ:AMGN) today announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus. The new plant is the first-of-its-kind in the U.S. and will use Amgen's proven next-generation biomanufacturing capabilities to manufacture products for the U.S. and global markets.
Categories: Category 2

Innovative technique converts white fat to brown fat

Wed, 08/01/2018 - 10:00
Brown fat tissue in the body can burn enormous amounts of energy to generate heat, and studies in humans and animals have suggested that increasing the amount of healthy brown fat might help weight management and reduce symptoms of diabetes. However, how to safely and effectively increase brown fat has been a significant challenge for researchers.
Categories: Category 2

Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention

Mon, 07/30/2018 - 20:01
Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is the first and only treatment specifically designed for migraine prevention to be approved in the European Union, Switzerland, the US and Australia.
Categories: Category 2

Researchers design a nano-carrier to release drugs into damaged cells

Fri, 07/27/2018 - 10:00
Senescent cells are damaged cells that do not perform their normal roles anymore but that are not dead -hence they are commonly known as zombi cells. These cells interfere with the functioning of the tissue in which they accumulate. Senescence is a cell program that is triggered by many types of damage and senescent cells are present in many diseases.
Categories: Category 2

Roche reports very strong performance in the first half of 2018

Thu, 07/26/2018 - 10:00
In the first half of 2018, Group sales rose 7% to CHF 28.1 billion and core EPS grew 19%. Excluding the effect of the US tax reform, core EPS grew 8%, ahead of sales. Core EPS growth reflects the strong underlying business performance. IFRS net income increased 33%, due to the underlying core results and lower impairment of intangible assets compared to 2017.
Categories: Category 2

Women and older people under-represented in drug trials for heart disease

Wed, 07/25/2018 - 10:00
Trying to determine how best to treat a patient, doctors often look to randomized clinical trials to guide their choice of what drug to prescribe. One of the most common illnesses is heart disease, and in recent years it's been proven that, contrary to popular belief, more women have heart problems than men do; similarly, it's more common for older people to have a heart condition than younger people. But do clinical trials reflect this reality?
Categories: Category 2

Atacand to be divested to Cheplapharm in Europe

Tue, 07/24/2018 - 10:00
AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe to Cheplapharm Arzneimittel GmbH (Cheplapharm). Atacand is a prescription medicine for the treatment of heart failure and hypertension.
Categories: Category 2

Novartis renews drug donation of Egaten® (triclabendazole) until 2022

Mon, 07/23/2018 - 10:00
Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) to extend its drug donation for Egaten® (triclabendazole) until 2022. Egaten is currently the only treatment for fascioliasis recommended by the WHO and is on the WHO Model List of Essential Medicines.

Categories: Category 2

FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation

Fri, 07/20/2018 - 12:00
The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first drug in its class (IDH1 inhibitors) and is approved for use with an FDA-approved companion diagnostic used to detect specific mutations in the IDH1 gene in patients with AML.
Categories: Category 2

Chemists characterize the fatal fungus among us

Fri, 07/20/2018 - 10:00
Life-threatening fungal infections affect more than two million people worldwide. Effective antifungal medications are very limited. Until now, one of the major challenges is that the fungal cell wall is poorly understood, which has impeded the development of effective antifungal medications that target the cell wall. However, an LSU chemist has identified for the first time the cell wall structure of one of the most prevalent and deadly fungi, which could usher in a new era of antifungal drug development to help save millions of lives.
Categories: Category 2

FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)

Thu, 07/19/2018 - 12:00
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer.
Categories: Category 2

Discovery of kidney cancer driver could lead to new treatment strategy

Thu, 07/19/2018 - 10:00
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change can lead to an overabundance of blood vessels, which help feed nutrients to the tumors. Their latest finding shows a potential new cancer-driving pathway.
Categories: Category 2
  • Profesionalumas.
    Esame savo srities specialistai ir mėgstame savo darbą, todėl darbų kokybę garantuojame.
  • Konkurencingumas.
    Poreikius atitinkantys sprendimai už konkurencingą kainą.
  • Konfidencialumas.
    Vertiname bendradarbiavimą, išlaikome konfidencialumą, siekiame tapti ilgalaikiu partneriu.